Clinical benefits and financial burden of pasireotide

The aim of this study is to perform a clinical and economic evaluation of pasireotide for patients with Cushing’s disease and acromegaly from the Bulgarian health insurance system point of view. A systematic review in internet-based databases for pasireotide efficacy and safety studies was performed. A top-down approach was applied to identify the medicines costs paid by the National Health Insurance Fund (NHIF) for the period 2016-2018. The costs were compared using statistical software MedCalc and extrapolated for the next 3 years applying linear functions. Mann-Whitney test for independent samples was applied for testing statistically significant differences. For more information click here.